ONCIMMUNE
Oncimmune (USA) LLC, founded in 2006, is an industry leader in early cancer detection. Oncimmune LLC is a wholly-owned subsidiary of Oncimmune LTD based in Nottingham, England. The company is committed to advancing early cancer detection through proprietary autoantibody assay technologies based on biological technology initially identified by John Robertson, M.D., professor of surgery at Nottingham University, England, and chief scientific officer of Oncimmune LTD. Ongoing research and developme... nt is conducted by Oncimmune under the direction of Dr. Robertson. The company’s mission is to develop early cancer detection tests to identify more than 90 percent of solid-tumor cancers, which make up 70 percent of all cancers including lung, breast, colorectal, prostate, stomach, pancreatic and ovarian. As a lab service, Oncimmune’s metro Kansas City laboratory is CLIA-certified under the Clinical Laboratory Improvements Amendment of 1988. Oncimmune LTD owns a portfolio of patents including No. 7,402,403 and No. 7,205,117.
ONCIMMUNE
Industry:
Biotechnology Commercial
Founded:
2006-01-01
Address:
Nottingham, Nottingham, United Kingdom
Country:
United Kingdom
Website Url:
http://www.oncimmune.com
Total Employee:
101+
Status:
Active
Contact:
+44 115 823 1869
Total Funding:
6.82 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Content Delivery Network Google Universal Analytics
Similar Organizations
Basilea Pharmaceutica
Basilea Pharmaceutica Ltd. is a commercial stage biopharmaceutical company.
BioConsortia
BioConsortia is developing highly effective microbial consortia for increasing agricultural yields.
Cibus
Cibus specializes in developing plant and microbial platforms .
Immutep
Immutep is a biopharmaceutical company developing immunotherapeutics in oncology.
Medicago
Medicago is a biotechnology company focused on the research, development, production, and commercialization of vaccines in Canada.
Ocugen
Ocugen is a clinical stage biopharmaceutical company.
Pliant Therapeutics
Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
Current Employees Featured
Matthew Hall CFO @ Oncimmune
CFO
Cameron Barnard Chief Business Officer @ Oncimmune
Chief Business Officer
Matthew Luttrell CCO @ Oncimmune
CCO
Adam M Hill Chief Executive Officer @ Oncimmune
Chief Executive Officer
John Robertson Founder @ Oncimmune
Founder
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2019-03-19 | Protagen | Protagen acquired by Oncimmune | 4.1 M GBP |
Investors List
SBRI Healthcare
SBRI Healthcare investment in Grant - Oncimmune
Claret Capital Partners
Claret Capital Partners investment in Debt Financing - Oncimmune
Balderton Capital
Balderton Capital investment in Venture Round - Oncimmune
Official Site Inspections
http://www.oncimmune.com
- Host name: ec2-3-10-218-137.eu-west-2.compute.amazonaws.com
- IP address: 3.10.218.137
- Location: London United Kingdom
- Latitude: 51.5164
- Longitude: -0.093
- Timezone: Europe/London
- Postal: EC2V
More informations about "Oncimmune"
Overview - Oncimmune
Oncimmune is a leading immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. With a partnership led …See details»
Antibody Biomarker Discovery Experts - Oncimmune
Our Technology & Science ImmunoINSIGHTS™ the analytical engine adding insights to your clinical data. Oncimmune has developed the most advanced and comprehensive analytical …See details»
Oncimmune - Crunchbase Company Profile & Funding
Oncimmune (USA) LLC, founded in 2006, is an industry leader in early cancer detection. Oncimmune LLC is a wholly-owned subsidiary of Oncimmune LTD …See details»
Our company - Oncimmune
Understanding diseases through the lens of the human immune system. Company Overview; About ImmunoINSIGHTS™ Biomarker Discovery; Targeted Panels & ArraysSee details»
Oncimmune - LinkedIn
Oncimmune’s ImmunoINSIGHTS platform enables life-science organisations to optimise drug development and delivery, leading to more effective targeted as well as safer treatments for patients ...See details»
Enabling Precision Medicine
Oncimmune is a precision medicine company, specialising in identifying autoantibody and antibody biomarkers for predicting and analysing immune interactions. Oncimmune enables …See details»
Oncimmune - The Org
Oncimmune is a leading immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease, and infectious diseases. Industries. Biotechnology. …See details»
Member profile: Oncimmune | BIA
Oncimmune is a pioneering precision medicine company, specialising in identifying unique autoantibody signatures. Using their novel ImmunoINSIGHTS™ platform, Oncimmune unlocks …See details»
Oncimmune Company Profile - Office Locations, Competitors
Oncimmune has 5 employees across 5 locations, $15 m in total funding, and £104 k in annual revenue in FY 2018. See insights on Oncimmune including office locations, competitors, …See details»
Oncimmune - Overview, News & Similar companies | ZoomInfo.com
Jul 12, 2023 View Oncimmune (www.oncimmune.com) location in Nottinghamshire, United Kingdom , revenue, industry and description. ... Oncimmune has announced that Martin …See details»
Oncimmune Holdings plc - AnnualReports.com
Oncimmune Holdings plc develops and commercializes technologies that enable cancer diagnosis in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, a blood test for early detection of lung …See details»
Oncimmune enters administration after failing to sell subsidiary
Feb 10, 2025 Oncimmune is a Leeds, England-based provider of autoantibody profiling research services to the pharmaceutical and biotechnology industry to enable delivery of precision …See details»
Oncimmune - VentureRadar
" Oncimmune® was founded in 2003 to commercialise technology developed in the laboratories of Professor John Robertson, a professor of surgery at Nottingham University. Research …See details»
Overview - Oncimmune
Oncimmune is a leading immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. Oncimmune has a diversified …See details»
Oncimmune » UK Healthcare Pavilion
Oncimmune's immuno-diagnostic test, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis. With over 200,000 tests already performed …See details»
Contact us - Oncimmune
For North American enquiries. Oncimmune LLC — One Broadway, 14th Floor Cambridge, MA 02142 USASee details»
Oncimmune - A spin-out from Nottingham Technology Ventures
Oncimmune has developed a powerful new approach to the early diagnosis of primary cancer, cancer recurrence and the clinical management of cancer. The technology is based on serum …See details»
Oncimmune Locations - Contract Research Map
Otto-Hahn-Str. 15 Dortmund, 44227 Germany Oncimmune, a global leader in biomarker services is focused on antibody (autoantibody) biomarker profiling in immuno-oncology, autoimmune …See details»
Roche signs up with Oncimmune to explore immunotherapy …
May 8, 2025 Oncimmune built out its immune profiling expertise with the £4.1 million ($5 million) acquisition of German biotech Protagen Diagnostics – which developed the SeroTag platform …See details»
Careers - Oncimmune
Oncimmune is a leader in immune biomarkers & immunodiagnostics, primarily focused on the growing in immuno-oncology, autoimmune disease and infectious diseases and we apply our …See details»